A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085)

被引：0
|
作者：
Yu, E.
Massard, C.
Gross, M.
Wilding, G.
Posadas, E.
Culine, S.
Carducci, M. A.
Trudel, G.
Paliwal, P.
Sternberg, C.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Louis Warschaw Prostate Canc Ctr, Los Angeles, CA USA
[4] UWCCC, Madison, WI USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] CHU Henri Mondor, F-94010 Creteil, France
[7] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] San Camillo Forlanini Hosp, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5147
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)
    Bilusic, M.
    Gulley, J. L.
    Heery, C.
    Apolo, A. B.
    Arlen, P. M.
    Rauckhorst, M.
    McMahon, S.
    Dahut, W. L.
    Schlom, J.
    Madan, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [32] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
    Chowdry, Rajasree Pia
    Ledet, Elisa M.
    Phelan, Mary C.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [34] DISEASE BURDEN OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN CHINA
    Ma, F. F.
    Liu, Q.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2020, 23 : S451 - S452
  • [35] Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)
    Lee, Daniel J.
    Cha, Eugene K.
    Dubin, Justin M.
    Beltran, Himisha
    Chromecki, Thomas F.
    Fajkovic, Harun
    Scherr, Douglas S.
    Tagawa, Scott T.
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2012, 109 (07) : 968 - +
  • [36] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Second line therapy for castration-resistant prostate cancer (CRPC)
    Molitor, B.
    Boergermann, C.
    UROLOGE, 2012, 51 (03): : 357 - 362
  • [38] Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease
    Smith, D. C.
    Smith, M. R.
    Small, E. J.
    Sweeney, C.
    Kurzrock, R.
    Gordon, M. S.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [39] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)
    Stein, M. N.
    Chen, Y.
    Hudes, G. R.
    Carducci, M. A.
    Tan, W.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345